By Maggie Fick LONDON (Reuters) - Novo Nordisk will launch its weight-loss drug Wegovy in Germany this month with the injection pen used in Norway and.
In a research note, UBS analyst Michael Leuchten has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged and still at GBX 12500.
AstraZeneca rebounds as analysts mull 'hard to read' cancer drug update proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
In his latest research note, analyst Michael Leuchten confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is still set at EUR 96..